Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

NCT02527200 on ClinicalTrials.gov · last registry update 2023-07-06

A small phase 3 — 56 participants, against a typical 424. The sponsor logged completion for 4 November 2020. Primary outcome, as filed: Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 56
Started: 2015-11-09
Primary completion: 2020-11-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks

Conditions studied

Metabolism and Nutrition Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.